Tim Hubbard is Director of ELIXIR, the European life sciences infrastructure, and Professor of bioinformatics at King's College London. He is also a member of the Technical Advisory Group for Genomics (TAG-G) at the World Health Organisation. Between 2013 and 2024 he was part time seconded to Genomics England for the 100,000 genomes project as part of work to mainstream whole genome sequencing for patient care in the National Health Service (NHS); to Health Data Research UK (HDRUK) to lead policy work on "Trusted Research Environments" (TREs); and to the NHS Data for R&D Programme for the Secure Data Environments (SDE) Network. Until 2013 he was Head of Informatics at the Wellcome Sanger Institute and one of the organisers of the sequencing of the human genome. In 1999 he co-founded the Ensembl project to analyse, organise and provide access to the human genome and from 2007 led the GENCODE project to annotate the structure of all human genes. Prior to that he studied biochemistry at the University of Cambridge, followed by a PhD in protein design at the Department of Crystallography, Birkbeck College, University of London and postdoctoral fellowships at the Protein Engineering Research Institute in Osaka under the EU scientific training program in Japan and MRC Centre, Cambridge.

Coming Soon

Miha is the founder and CTO of Genialis, the RNA Biomarker company. He led the development of a pioneering biomarker based on RNA-seq and machine learning, which was accepted by the FDA for clinical trial use. Passionate about data integration and (X)AI, Miha co-developed the Orange data mining suite and the Resolwe bioinformatics engine. He earned his doctorate in computer science at University of Ljubljana and completed postdoctoral research at Baylor College of Medicine. In his free time, Miha enjoys mountain adventures and sailing the Adriatic.

Francisco Azuaje, PhD, is the Director of Bioinformatics at Genomics England, where he provides cross-cutting leadership in strategy and research with a focus on data science and AI. With a career covering academia, the pharmaceutical industry, and the public sector, Dr. Azuaje has wide experience leading multidisciplinary teams in solving challenges involving diverse data sources and computational modelling approaches. These include multi-omics data, clinical and pre-clinical imaging, natural language data, and real-world evidence for diagnostic purposes, therapeutic discovery and other clinically relevant applications.

Coming Soon

Zoe Kourtzi is a Professor of Computational Cognitive Neuroscience at the University of Cambridge. Zoe’s research aims to develop predictive models of neurodegenerative disease and mental health with translational impact in early diagnosis and personalised interventions. Zoe received her PhD from Rutgers University and was a postdoctoral fellow at MIT and Harvard. She was a Senior Research Scientist at the Max Planck Institute for Biological Cybernetics and then a Chair in Brain Imaging at the University of Birmingham, before moving to the University of Cambridge in 2013. She is a Royal Society Industry Fellow, Cambridge University Lead at the Alan Turing Institute and Co-director of Cambridge’s Centre for Data Driven Discovery.

Deogratias received his Ph.D. from the University of Kent on the Applications of Artificial Intelligence in healthcare in 2020. He previously did his master's in AI at Tianjin University, in China. Deogratias has been researching and practicing machine learning, deep learning, image and voice signal processing which are the core elements of Artificial Intelligence, since 2012. During his time in China, he also worked for GTA, a big data analytic company based in Shenzhen, China as a data scientist. The company recruited him while he was still doing his master’s degree. While in China, Deogratias and his friend, formed a team that became second runners in the international innovation competition for automation and UAV in 2014. In 2019, he was among the 15 AI researchers who received the IEEE Outstanding Young Investigator Research Visit award to Sapienza University, Italy. His research interests are in the application of deep learning, machine learning, data analysis, and including explainable AI systems, super resolution, virtual and augmented reality. He has published several papers in peer-reviewed journals including Nature and IEEE. He has a total of 2653 citations, 11 h-Index and 13 i10-Index. Some of his published work has featured in global media houses including Forbes and the BBC. Deogratias has conducted AI based consultation works for the UNDP, UNICEF, UNU and the Tanzania ministry of health. Deogratias has received a grant from Google to develop an AI based screening tool for breast cancer, a grant from the Lacuna fund to develop machine learning ready dataset for predictions of Rabies outbreak. Recently, Dr Deogratias has won a grant from the IDRC to develop AI algorithm for screening of TB among people living with HIV. He is currently leading the Emerging Technologies for Health Research and Development laboratory at MUHAS (ETH) which utilises emerging technologies like AI, VR, AR and Blockchain technologies to develop healthcare solutions. Deogratias is currently serving as a secretariate member for the Lacuna fund.

Coming Soon

I am a Senior Researcher at the National Cancer Institute (INCA), leading the Bioinformatics and Computational Biology Laboratory. Additionally, I am a faculty member of the Postgraduate Program in Oncology at INCA, a Fellow of the FAPERJ Young Researcher Program from Our State, and a CNPq Level 2 Productivity Fellow. I am also the co-founder of the startup OneSkin.

I hold a bachelor's and master's degree in Biochemistry from the Federal University of Viçosa and a PhD in Bioinformatics from the Federal University of Minas Gerais, which included a sandwich period at the NIH in Bethesda, United States. I gained postdoctoral proficiency in Bioinformatics from the Gene Center at Ludwig Maximilian University of Munich, Germany, and the Center for Computational Biology at the Cancer and Genomic Sciences Institute at the University of Birmingham, England, as a Visiting Researcher.

My expertise lies in Bioinformatics, Molecular Biology, and Biochemistry, with a focus on the analysis and integration of genomics, epigenomics, and transcriptomics data, as well as the application of artificial intelligence techniques in cancer biology.

Coming Soon

Philip M. Kim is a professor at the University of Toronto at the Donnelly Centre and the Departments of Computer Science and Molecular Genetics. In his academic research, he has been developing novel machine learning methods for protein and peptide engineering and authored over 100 publications, 7 invention disclosures and 5 patent applications. He has co-founded several biotechnology companies, including Fable Therapeutics and TBG Therapeutics and serves as consultant and member of the scientific advisory board for others. Before setting up his lab in 2009, he was a postdoctoral fellow at Yale University and an associate with McKinsey & Co. He holds a Ph.D. from the Artificial Intelligence Laboratory and Department of Chemistry at the Massachusetts Institute of Technology and a B.S. in Physics and Biochemistry from the University of Tuebingen.

“I have always been fascinated by how scientists and members of the public engage with controversial scientific topics. I’m interested in how genomics and data shape and are shaped by their social and cultural context and how we create conversations about the kinds of futures that we want.”

Richard is a sociologist of science, technology and medicine. Richard’s interests are in the interface between science and the public, particularly around how scientists and members of the public engage with controversial scientific topics and the possible futures created by new science and technology.  This includes a focus on the social and ethical challenges associated with scientific advance – something that he has explored in relation to biotechnology, ageing and dementia, and latterly genomics, big data and medical applications of artificial intelligence. His research, drawing on qualitative, ethnographic and quantitative approaches, has been published widely in both social science and biomedical journals, reflecting a commitment to engaging with interdisciplinary audiences.  He is also the Deputy Director and Research Lead for the Kavli Centre for Ethics, Science, and the Public at the University of Cambridge.

Darlington Akogo is a global leader in Artificial Intelligence. He's the Founder and Chief Executive Officer at minoHealth AI Labs; an AI Healthtech company; karaAgro AI; an AI-powered Plant & Pest Disease Detection and Precision Agriculture platform, Runmila AI Institute; an AI and Data Science training institute, and Gudra AI Studio; an organization broadly exploring AI and Exponential Technologies applied various domains including Transportation, Sanitation and Energy. 

Akogo has been named one of the Global Top 100 Most Influential People of African Descent (MIPAD) in Healthcare. He's the Chair (Topic Driver) of the Topic Group on AI for Radiology under the United Nations International Telecommunications Union (ITU) and World Health Organization (WHO) Focus Group on 'Artificial Intelligence for Health' (FG-AI4H). At UN FG-AI4H, Akogo leads the development of global regulations and standards for AI in radiology. He also works with African Union, where he serves as the Chair for the working group on Artificial Intelligence Economy, working towards the development of a Continental African Union (AU) Artificial Intelligence (AI) Continental Strategy that includes legislative, regulatory, ethical, policy, and infrastructural frameworks in consultation with stakeholders such as AU Member States’ governments, private sector, academia, innovators, and consumers. 

He serves as a Global Innovation Adviser (GIA) to the International Development Innovation Alliance (IDIA), where he provides advice on how to ensure international development agencies are implementing responsible and localized Emerging Technology across the various countries they are in. IDIA is an alliance between the top 15 international development agencies with the shared goal of “actively promoting and advancing innovation as a means to help achieve sustainable development”. Its members include the Rockefeller Foundation, Bill & Melinda Gates Foundation, Global Affairs Canada, Dutch Ministry of Foreign Affairs, Deutsche Gesellschaft für Internationale Zusammenarbeit GmbH (GIZ), Global Innovation Fund, Grand Challenges Canada, Skoll Foundation, Swedish International Development Cooperation Agency  (Sida), UNICEF, and USAID.  

He’s a Research Co-Investigator, Data Management Lead, and Chair of Data group for the project “NIHR Global Health Research Group on Digital Diagnostics for African Health Systems”, led by Imperial College London in partnership with minoHealth AI Labs and other organizations, with prior funding from UKRI. He served as the co-chair of the Digital Health & AI Global Health Strategy Group, created by University of Oxford and 13 partners from around the world including minoHealth AI Labs, Robert Koch Institute, Charité - Universitätsmedizin Berlin, London School of Hygiene & Tropical Medicine, Oxford University Clinical Research Unit - OUCRU Vietnam, Financial Times, Technische Universität Berlin, Clinical Information Network - KEMRI / Wellcome Trust Programme, Aga Khan Development Network.

Coming Soon

Coming Soon